Mesenchymal Stromal Cells Mediate Clinically Unpromising but Favourable Immune Responses in Kidney Transplant Patients
Background. Allograft rejection postkidney transplantation (KTx) is a major clinical challenge despite increased access to a healthcare system and improvement in immunosuppressive (IS) drugs. In recent years, mesenchymal stromal cells (MSCs) have aroused considerable interest in field of transplanta...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.1155/2022/2154544 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564067905044480 |
|---|---|
| author | Urvashi Kaundal Raja Ramachandran Amit Arora Deepesh B. Kenwar Ratti Ram Sharma Ritambhra Nada Mukut Minz Vivekanand Jha Aruna Rakha |
| author_facet | Urvashi Kaundal Raja Ramachandran Amit Arora Deepesh B. Kenwar Ratti Ram Sharma Ritambhra Nada Mukut Minz Vivekanand Jha Aruna Rakha |
| author_sort | Urvashi Kaundal |
| collection | DOAJ |
| description | Background. Allograft rejection postkidney transplantation (KTx) is a major clinical challenge despite increased access to a healthcare system and improvement in immunosuppressive (IS) drugs. In recent years, mesenchymal stromal cells (MSCs) have aroused considerable interest in field of transplantation due to their immunomodulatory and regenerative properties. This study was aimed at investigating safety, feasibility, and immunological effects of autologous MSCs (auto-MSCs) and allogeneic MSCs (allo-MSCs) as a complement to IS drug therapy in KTx patients. Methods. 10 patients undergoing KTx with a living-related donor were analysed along with 5 patients in the control group. Patients were given auto-MSCs or allo-MSCs at two time points, i.e., one day before transplant (D-0) and 30 days after transplant (D-30) at the rate of 1.0-1.5×106 MSCs per kg body weight in addition to immunosuppressants. Patients were followed up for 2 years, and 29 immunologically relevant lymphocyte subsets and 8 cytokines and important biomarkers were analysed at all time points. Results. Patients displayed no signs of discomfort or dose-related toxicities in response to MSC infusion. Flow cytometric analysis revealed an increase in B regulatory lymphocyte populations and nonconventional T regulatory cells and a decrease in T effector lymphocyte proportions in auto-MSC-infused patients. No such favourable immune responses were observed in all MSC-infused patients. Conclusion. This study provides evidence that auto-MSCs are safe and well tolerated. This is the first ever report to compare autologous and allogeneic MSC infusion in KTx patients. Importantly, our data demonstrated that MSC-induced immune responses in patients did not completely correlate with clinical outcomes. Our findings add to the current perspective of using MSCs in KTx and explore possibilities through which donor/recipient chimerism can be achieved to induce immune tolerance in KTx patients. |
| format | Article |
| id | doaj-art-93246860236b4b9b8ccce12ec8bced91 |
| institution | Kabale University |
| issn | 1687-9678 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stem Cells International |
| spelling | doaj-art-93246860236b4b9b8ccce12ec8bced912025-02-03T01:11:56ZengWileyStem Cells International1687-96782022-01-01202210.1155/2022/2154544Mesenchymal Stromal Cells Mediate Clinically Unpromising but Favourable Immune Responses in Kidney Transplant PatientsUrvashi Kaundal0Raja Ramachandran1Amit Arora2Deepesh B. Kenwar3Ratti Ram Sharma4Ritambhra Nada5Mukut Minz6Vivekanand Jha7Aruna Rakha8Department of Translational and Regenerative MedicineDepartment of NephrologyDepartment of Medical MicrobiologyDepartment of Renal Transplant SurgeryDepartment of Transfusion MedicineDepartment of HistopathologyFortis HospitalThe George Institute for Global HealthDepartment of Translational and Regenerative MedicineBackground. Allograft rejection postkidney transplantation (KTx) is a major clinical challenge despite increased access to a healthcare system and improvement in immunosuppressive (IS) drugs. In recent years, mesenchymal stromal cells (MSCs) have aroused considerable interest in field of transplantation due to their immunomodulatory and regenerative properties. This study was aimed at investigating safety, feasibility, and immunological effects of autologous MSCs (auto-MSCs) and allogeneic MSCs (allo-MSCs) as a complement to IS drug therapy in KTx patients. Methods. 10 patients undergoing KTx with a living-related donor were analysed along with 5 patients in the control group. Patients were given auto-MSCs or allo-MSCs at two time points, i.e., one day before transplant (D-0) and 30 days after transplant (D-30) at the rate of 1.0-1.5×106 MSCs per kg body weight in addition to immunosuppressants. Patients were followed up for 2 years, and 29 immunologically relevant lymphocyte subsets and 8 cytokines and important biomarkers were analysed at all time points. Results. Patients displayed no signs of discomfort or dose-related toxicities in response to MSC infusion. Flow cytometric analysis revealed an increase in B regulatory lymphocyte populations and nonconventional T regulatory cells and a decrease in T effector lymphocyte proportions in auto-MSC-infused patients. No such favourable immune responses were observed in all MSC-infused patients. Conclusion. This study provides evidence that auto-MSCs are safe and well tolerated. This is the first ever report to compare autologous and allogeneic MSC infusion in KTx patients. Importantly, our data demonstrated that MSC-induced immune responses in patients did not completely correlate with clinical outcomes. Our findings add to the current perspective of using MSCs in KTx and explore possibilities through which donor/recipient chimerism can be achieved to induce immune tolerance in KTx patients.http://dx.doi.org/10.1155/2022/2154544 |
| spellingShingle | Urvashi Kaundal Raja Ramachandran Amit Arora Deepesh B. Kenwar Ratti Ram Sharma Ritambhra Nada Mukut Minz Vivekanand Jha Aruna Rakha Mesenchymal Stromal Cells Mediate Clinically Unpromising but Favourable Immune Responses in Kidney Transplant Patients Stem Cells International |
| title | Mesenchymal Stromal Cells Mediate Clinically Unpromising but Favourable Immune Responses in Kidney Transplant Patients |
| title_full | Mesenchymal Stromal Cells Mediate Clinically Unpromising but Favourable Immune Responses in Kidney Transplant Patients |
| title_fullStr | Mesenchymal Stromal Cells Mediate Clinically Unpromising but Favourable Immune Responses in Kidney Transplant Patients |
| title_full_unstemmed | Mesenchymal Stromal Cells Mediate Clinically Unpromising but Favourable Immune Responses in Kidney Transplant Patients |
| title_short | Mesenchymal Stromal Cells Mediate Clinically Unpromising but Favourable Immune Responses in Kidney Transplant Patients |
| title_sort | mesenchymal stromal cells mediate clinically unpromising but favourable immune responses in kidney transplant patients |
| url | http://dx.doi.org/10.1155/2022/2154544 |
| work_keys_str_mv | AT urvashikaundal mesenchymalstromalcellsmediateclinicallyunpromisingbutfavourableimmuneresponsesinkidneytransplantpatients AT rajaramachandran mesenchymalstromalcellsmediateclinicallyunpromisingbutfavourableimmuneresponsesinkidneytransplantpatients AT amitarora mesenchymalstromalcellsmediateclinicallyunpromisingbutfavourableimmuneresponsesinkidneytransplantpatients AT deepeshbkenwar mesenchymalstromalcellsmediateclinicallyunpromisingbutfavourableimmuneresponsesinkidneytransplantpatients AT rattiramsharma mesenchymalstromalcellsmediateclinicallyunpromisingbutfavourableimmuneresponsesinkidneytransplantpatients AT ritambhranada mesenchymalstromalcellsmediateclinicallyunpromisingbutfavourableimmuneresponsesinkidneytransplantpatients AT mukutminz mesenchymalstromalcellsmediateclinicallyunpromisingbutfavourableimmuneresponsesinkidneytransplantpatients AT vivekanandjha mesenchymalstromalcellsmediateclinicallyunpromisingbutfavourableimmuneresponsesinkidneytransplantpatients AT arunarakha mesenchymalstromalcellsmediateclinicallyunpromisingbutfavourableimmuneresponsesinkidneytransplantpatients |